The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura [PDF]
Vojnosanitetski Pregled, 2013 Backround/Aim. The final diagnosis of malignant pleural mesothelioma is made exclusively by histopathological examination of biopsy materials that are routinely complemented by the use of immunohistochemical analysis.
Panjković Milana +5 more
doaj +1 more source
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Frontiers in Oncology, 2020 Malignant pleural mesothelioma (MPM) is an uncommon but aggressive and treatment resistant neoplasm with low survival rates. In the last years we assisted to an exponential growth in the appreciation of mesothelioma pathobiology, leading several new ...
L. Cantini +3 more
semanticscholar +1 more source
The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy [PDF]
, 2017 Objectives: Contrast-enhanced computed tomography (CT) provides essential cross-sectional imaging data in patients with suspected pleural malignancy (PM). The performance of CT in routine practice may be lower than in previously reported research. We
Alexander, Laura +4 more
core +1 more source
Orphanet Journal of Rare Diseases, 2008 Malignant mesothelioma is a fatal asbestos-associated malignancy originating from the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica vaginalis.
Parker Robert J +2 more
doaj +1 more source
Estimating past inhalation exposure to asbestos: a tool for risk attribution and disease screening [PDF]
, 2017 Introduction: Late presentation is common in mesothelioma. Reliable assessment of past exposure to asbestos is a necessary first step for risk attribution and for the development of a future screening programme. Such a programme could maximise access
Blyth, Kevin G. +2 more
core +1 more source
Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast [PDF]
, 2015 Background: Metastases to the breast from extramammary malignancies are very rare, and ruling out the diagnosis of primary breast tumor is important in order to decide on clinical management and predict prognosis.
Derme, Martina +5 more
core +2 more sources
Clinical significance of histologic subtyping of malignant pleural mesothelioma
Translational Lung Cancer Research, 2020 Malignant mesothelioma (MM) is uncommon, but very aggressive tumor arising from the mesothelial cells of pleura, pericardium, peritoneum, and tunica vaginalis. Despite multimodality treatments 5-year survival is only 5% after the diagnosis. Histology and
L. Brčić, I. Kern
semanticscholar +1 more source
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. [PDF]
, 2016 Malignant pleural mesothelioma (MPM), a rare malignancy with a poor prognosis, is mainly caused by exposure to asbestos or other organic fibers, but the underlying genetic mechanism is not fully understood.
Fang, Li Tai +11 more
core +3 more sources
Pemetrexed and malignant pleural mesothelioma
Annals of Oncology, 2006 Malignant Pleural Mesothelioma (MPM) continues to be a challenging problem; because few patients may be treated with radical surgery and conventional chemotherapy have achieved very dismal results. Pemetrexed is a new drug with multitarget antifolate activity which seems to be particularly active in many solid tumors and also in MPM.
M. Marangolo, Bernadette Vertogen
openalex +4 more sources
SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma [PDF]
, 2018 SYSTEMS-2 is a randomised study of radiotherapy dose escalation for pain control in 112 patients with malignant pleural mesothelioma (MPM). Standard palliative (20Gy/5#) or dose escalated treatment (36Gy/6#) will be delivered using advanced radiotherapy ...
Alexander, L. +11 more
core +2 more sources